Viral vector manufacturing continues to face challenges in delivering consistent quality and achieving high productivity at scale. This webinar will highlight how CDMO innovation drives improvements ...
COLLEGE STATION, Texas, Nov. 3, 2025 /PRNewswire/ -- Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector CDMO specializing in advanced therapies, today announced a strategic partnership ...
Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. As gene therapy technology becomes more advanced, producing viral vectors becomes ...
BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus ...
Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...
Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the launch of its new corporate brand. Oxford Biomedica is rebranding as OXB, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback